Cargando…
Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis
BACKGROUND: Hyperlipidemia is a metabolic disease characterized by elevated levels of blood lipids and lipoproteins and a major pathogenic factor of atherosclerosis. In China, Erchen decoction (ECD) has been widely used to treat hyperlipidemia. However, there is no systematic review found. In order...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572033/ https://www.ncbi.nlm.nih.gov/pubmed/33080674 http://dx.doi.org/10.1097/MD.0000000000022374 |
_version_ | 1783597265267458048 |
---|---|
author | Luo, Huan Xiong, Min Zhu, Wenyu Shen, Tao |
author_facet | Luo, Huan Xiong, Min Zhu, Wenyu Shen, Tao |
author_sort | Luo, Huan |
collection | PubMed |
description | BACKGROUND: Hyperlipidemia is a metabolic disease characterized by elevated levels of blood lipids and lipoproteins and a major pathogenic factor of atherosclerosis. In China, Erchen decoction (ECD) has been widely used to treat hyperlipidemia. However, there is no systematic review found. In order to evaluate the efficacy and safety of ECD in the treatment of hyperlipidemia, we need to conduct a meta-analysis and systematic evaluation. METHODS: We will enroll the randomized controlled trials (RCTs) evaluating the effectiveness and safety of ECD in the treatment of hyperlipidemia. Data come mainly from 4 Chinese databases (China national knowledge infrastructure, Wanfang, Chinese biomedical literature database, and VIP Database) and 4 English databases (Pubmed, Embase excerpt medica database, Cochrane Library, and Web of science). The enrollment of RCTs is from the starting date of database establishment till September 30, 2020. Low density lipoprotein cholesterol is considered as the main indicator of the dyslipidemia, while the serum concentrations of total cholesterol, triglyceride, high density lipoprotein cholesterol, apolipoprotein A, and apolipoprotein B are regarded as the secondary indicators. There are Safety indicators including liver enzyme, kidney function and fasting blood glucose. The work such as selection of literature, data collection, quality evaluation of included literature, and assessment of publication bias will be conducted by 2 independent researchers. Meta-analysis will be performed by RevMan 5.0 software. RESULTS: This study will provide high-quality evidence for the effectiveness and safety of ECD in the treatment of hyperlipidemia. CONCLUSION: The results of the study will help us determine whether ECD can effectively treat hyperlipidemia. ETHICS AND DISSEMINATION: This study does not require ethical approval. We will disseminate our findings by publishing results in a peer-reviewed journal. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/GZ69F |
format | Online Article Text |
id | pubmed-7572033 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-75720332020-10-29 Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis Luo, Huan Xiong, Min Zhu, Wenyu Shen, Tao Medicine (Baltimore) 3800 BACKGROUND: Hyperlipidemia is a metabolic disease characterized by elevated levels of blood lipids and lipoproteins and a major pathogenic factor of atherosclerosis. In China, Erchen decoction (ECD) has been widely used to treat hyperlipidemia. However, there is no systematic review found. In order to evaluate the efficacy and safety of ECD in the treatment of hyperlipidemia, we need to conduct a meta-analysis and systematic evaluation. METHODS: We will enroll the randomized controlled trials (RCTs) evaluating the effectiveness and safety of ECD in the treatment of hyperlipidemia. Data come mainly from 4 Chinese databases (China national knowledge infrastructure, Wanfang, Chinese biomedical literature database, and VIP Database) and 4 English databases (Pubmed, Embase excerpt medica database, Cochrane Library, and Web of science). The enrollment of RCTs is from the starting date of database establishment till September 30, 2020. Low density lipoprotein cholesterol is considered as the main indicator of the dyslipidemia, while the serum concentrations of total cholesterol, triglyceride, high density lipoprotein cholesterol, apolipoprotein A, and apolipoprotein B are regarded as the secondary indicators. There are Safety indicators including liver enzyme, kidney function and fasting blood glucose. The work such as selection of literature, data collection, quality evaluation of included literature, and assessment of publication bias will be conducted by 2 independent researchers. Meta-analysis will be performed by RevMan 5.0 software. RESULTS: This study will provide high-quality evidence for the effectiveness and safety of ECD in the treatment of hyperlipidemia. CONCLUSION: The results of the study will help us determine whether ECD can effectively treat hyperlipidemia. ETHICS AND DISSEMINATION: This study does not require ethical approval. We will disseminate our findings by publishing results in a peer-reviewed journal. OSF REGISTRATION NUMBER: DOI 10.17605/OSF.IO/GZ69F Lippincott Williams & Wilkins 2020-10-16 /pmc/articles/PMC7572033/ /pubmed/33080674 http://dx.doi.org/10.1097/MD.0000000000022374 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 3800 Luo, Huan Xiong, Min Zhu, Wenyu Shen, Tao Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis |
title | Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis |
title_full | Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis |
title_fullStr | Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis |
title_full_unstemmed | Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis |
title_short | Erchen decoction for hyperlipemia: Protocol for a systematic review and meta-analysis |
title_sort | erchen decoction for hyperlipemia: protocol for a systematic review and meta-analysis |
topic | 3800 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572033/ https://www.ncbi.nlm.nih.gov/pubmed/33080674 http://dx.doi.org/10.1097/MD.0000000000022374 |
work_keys_str_mv | AT luohuan erchendecoctionforhyperlipemiaprotocolforasystematicreviewandmetaanalysis AT xiongmin erchendecoctionforhyperlipemiaprotocolforasystematicreviewandmetaanalysis AT zhuwenyu erchendecoctionforhyperlipemiaprotocolforasystematicreviewandmetaanalysis AT shentao erchendecoctionforhyperlipemiaprotocolforasystematicreviewandmetaanalysis |